1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Impact of proteasome inhibitor MG-132 on expression of NF-κB, IL-1β and histological remodeling after myocardial infarction

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of the present study was to investigate the impact of carbobenzoxy-Leu-Leu-leucinal (MG-132) on myocardial remodeling in rats with myocardial infarction (MI) and investigate the possible underlying mechanisms. The rat model of MI was established, followed by administration of MG-132 (MG group), pyrrolidine dithiocarbamic acid (PDTC group) or normal saline (MI group) for 28 days. The expression of nuclear factor-κB (NF-κB) p65, interleukin 1β (IL-1β) and matrix metalloproteinase 2 (MMP-2), as well as the total volume of collagen and the ratio of type I/III collagen were then detected. Total collagen, including type I and III collagen, and the ratio of type I/III collagen were significantly increased in MI rats compared with those in the sham group (P<0.01), while it was significantly decreased in the PDTC and MG groups compared with that in the MI group (P<0.01). A similar trend was identified for the expression of NF-κB, IL-1β and MMP-2, which was significantly increased in the MI group compared with that in the sham group (P<0.01), while it was significantly decreased in the MG and PDTC groups compared with that in the MI group (P<0.01). In conclusion, MG-132 was demonstrated to improve post-MI tissue remodeling, and the mechanism may be associated with the inhibition of NF-κB activation and the downregulation of inflammatory cytokines, such as IL-1β.

          Related collections

          Author and article information

          Journal
          Exp Ther Med
          Exp Ther Med
          ETM
          Experimental and Therapeutic Medicine
          D.A. Spandidos
          1792-0981
          1792-1015
          August 2018
          13 June 2018
          13 June 2018
          : 16
          : 2
          : 1365-1372
          Affiliations
          [1 ]Department of Cardiology, The First Affiliated Hospital of Dali University, Dali, Yunnan 671000, P.R. China
          [2 ]Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 404100, P.R. China
          Author notes
          Correspondence to: Professor Zhangrong Chen, Department of Cardiology, The First Affiliated Hospital of Dali University, 32 Jiashibo Avenue, Dali, Yunnan 671000, P.R. China, E-mail: cnzhangrongchen@ 123456163.com
          Article
          PMC6090422 PMC6090422 6090422 ETM-0-0-6308
          10.3892/etm.2018.6308
          6090422
          30112065
          5a580d71-7469-4f04-b87a-194eccee7294
          Copyright © 2018, Spandidos Publications
          History
          : 14 April 2017
          : 01 September 2017
          Categories
          Articles

          proteasome inhibitor,nuclear factor-κB,myocardial remodeling,myocardial infarction,interleukin-1β

          Comments

          Comment on this article